Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?

Lignende værker

• Experience with Bilateral Risk-Reducing Mastectomy for an Unaffected BRCA Mutation Carrier
  af: Maeshima, Yurina, et al.
  Udgivet: (2016)
• Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers
  af: Lee, Eun-Gyeong, et al.
  Udgivet: (2019)
• What The Surgeons Should Know About The Bilateral Prophylactic Mastectomy in BRCA Mutation Carriers
  af: Franceschini, Gianluca, et al.
  Udgivet: (2019)
• BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study
  af: Kitson, Sarah J., et al.
  Udgivet: (2020)
• Can multiple SNP testing in BRCA2 and BRCA1 female carriers be used to improve risk prediction models in conjunction with clinical assessment?
  af: Prosperi, Mattia CF, et al.
  Udgivet: (2014)